The latest price target for Coherus Oncology (NASDAQ:CHRS) was reported by Maxim Group on September 4, 2025. The analyst firm set a price target for $4.00 expecting CHRS to rise to within 12 months (a possible 189.86% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Coherus Oncology (NASDAQ:CHRS) was provided by Maxim Group, and Coherus Oncology upgraded their buy rating.

The last upgrade for Coherus Oncology Inc happened on September 4, 2025 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for Coherus Oncology Inc.

The last downgrade for Coherus Oncology Inc happened on August 16, 2024 when UBS changed their price target from $4 to $1.5 for Coherus Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus Oncology was filed on September 4, 2025 so you should expect the next rating to be made available sometime around September 4, 2026.

While ratings are subjective and will change, the latest Coherus Oncology (CHRS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Coherus Oncology (CHRS) is trading at is $1.38, which is within the analyst’s predicted range.